The AbbVie (ABBV) Given Daily News Impact Score of 0.28

The AbbVie (ABBV) Given Daily News Impact Score of 0.28

Shares of AbbVie (ABBV) traded up 1.05% during mid-day trading on Thursday, hitting $66.71. The original version of this news story can be read at It has outperformed by 24.08% the S&P500. California Public Employees Retirement System reported 0.46% in AbbVie Inc.

In other news, SVP Azita Saleki-Gerhardt sold 8,300 shares of the firm's stock in a transaction that occurred on Monday, September 11th. Raymond James & Associates owns 0.81% invested in AbbVie Inc. The stock decreased 0.94% or $0.9 during the last trading session, reaching $94.51. About 5.11M shares traded. It has underperformed by 6.07% the S&P500. They expect $1.41 earnings per share, up 11.90% or $0.15 from last year's $1.26 per share. QCOM's profit will be $1.14B for 21.04 P/E if the $0.77 EPS becomes a reality. After $1.41 actual EPS reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 1.42% EPS growth. (NYSE:ABBV) news were published by: which released: "AbbVie Raises Dividend 11%... What Now?" on December 04, 2017.'s news article titled: "ICON Wins Best Contract Research Organisation at the Annual Scrip Awards 2017" with publication date: November 30, 2017 was also an interesting one. (NYSE:ABBV). Morgan Stanley owns 14.01 million shares or 0.31% of their United States portfolio. It also increased its holding in Cummins Inc (NYSE:CMI) by 38,851 shares in the quarter, for a total of 49,751 shares, and has risen its stake in Level 3 Communications Inc (Put) (NYSE:LVLT).

Sell side analysts plays vital role in buying and selling a stock where 3 analysts rated AbbVie Inc. Therefore 42% are positive. Orchids Paper Products Co had 4 analyst reports since October 15, 2015 according to SRatingsIntel. On Friday, October 13 the stock rating was maintained by UBS with "Neutral". Following the completion of the sale, the senior vice president now directly owns 93,099 shares in the company, valued at approximately $7,915,276.98. The rating was initiated by Societe Generale on Wednesday, April 6 with "Sell". The firm has "Equal-Weight" rating given on Tuesday, December 1 by Barclays Capital. Vetr lowered AbbVie from a "strong-buy" rating to a "buy" rating and set a $71.84 price objective on the a research note on Monday, May 15th. On Wednesday, June 8 the stock rating was downgraded by Morgan Stanley to "Equal-Weight".

Analysts await AbbVie Inc. (NYSE:ABBV). Kidder Stephen W, Massachusetts-based fund reported 36,805 shares. The company has a market cap of $106.17 billion, a PE ratio of 17.29 and a beta of 1.57. Df Dent And has invested 0.01% in AbbVie Inc. On Wednesday, June 14 ALBAN CARLOS sold $3.21M worth of AbbVie Inc.

More news: Ladbrokes Coral and GVC Holdings in 'detailed' talks about £3.9bn merger

Walleye Trading Llc, which manages about $16.31B US Long portfolio, upped its stake in Onemain Hldgs Inc (Call) by 304,700 shares to 469,300 shares, valued at $11.54 million in 2017Q2, according to the filing. (ABBV) - averaging the work of different analysts - reveals a mean PT of $99.14/share. (NYSE:ABBV). Fjarde Ap reported 0.53% of its portfolio in AbbVie Inc. Therefore 100% are positive. AbbVie Inc. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32. Peavine Cap Ltd Co invested 0.89% in AbbVie Inc. (NYSE:ABBV) rating on Friday, August 18. The company has a consensus rating of "Buy" and an average target price of $96.66. (NASDAQ:QCOM), 15 have Buy rating, 1 Sell and 20 Hold. AbbVie earned a news impact score of 0.28 on AlphaOne's scale. Greenleaf Tru accumulated 33,928 shares or 0.06% of the stock. RBC Capital Markets maintained The Toronto-Dominion Bank (TSE:TD) rating on Tuesday, October 25.

The return on assets (ROA) (aka return on total assets, return on average assets), is one of the most widely used profitability ratios because it is related to both profit margin and asset turnover, and shows the rate of return for both creditors and investors of the company. Finally, BMO Capital Markets set a $84.00 price target on AbbVie and gave the company a "hold" rating in a report on Monday. (NYSE:ABBV) has "Market Perform" rating given on Friday, June 10 by BMO Capital Markets. The rating was initiated by William Blair on Friday, February 5 with "Outperform".

AbbVie Inc. has a 1 year low of $58.80 and a 1 year high of $98.52. (NYSE:ABBV) news were published by: which released: "Dividend Aristocrats In Focus Part 45: AbbVie" on November 22, 2017, also with their article: "The case for Johnson & Johnson" published on November 21, 2017, published: "AbbVie's risankizumab successful in fourth late-stage psoriasis study" on December 04, 2017. Middleton And Ma has invested 2.17% in AbbVie Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.